Bradley Foster & Sargent Inc. CT Cuts Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Bradley Foster & Sargent Inc. CT lowered its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 23.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,496 shares of the company’s stock after selling 11,430 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Privia Health Group were worth $713,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Financial Management Professionals Inc. acquired a new stake in shares of Privia Health Group during the 4th quarter valued at approximately $51,000. Quarry LP increased its stake in Privia Health Group by 344.6% in the 3rd quarter. Quarry LP now owns 3,268 shares of the company’s stock valued at $60,000 after purchasing an additional 2,533 shares in the last quarter. KBC Group NV raised its holdings in Privia Health Group by 34.6% during the third quarter. KBC Group NV now owns 3,385 shares of the company’s stock worth $62,000 after purchasing an additional 871 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in Privia Health Group during the third quarter worth $66,000. Finally, Values First Advisors Inc. acquired a new stake in Privia Health Group in the third quarter valued at $83,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Stock Down 0.5 %

Shares of PRVA stock opened at $24.52 on Friday. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $25.67. The firm’s 50 day moving average price is $21.99 and its two-hundred day moving average price is $20.40. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of 245.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Macquarie assumed coverage on Privia Health Group in a research note on Monday, December 16th. They set an “outperform” rating and a $25.00 price target for the company. Needham & Company LLC assumed coverage on shares of Privia Health Group in a research report on Friday, January 10th. They set a “buy” rating and a $25.00 target price for the company. Truist Financial upped their price target on shares of Privia Health Group from $24.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 8th. JPMorgan Chase & Co. raised their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, November 29th. Finally, Stephens reaffirmed an “overweight” rating and issued a $26.00 target price on shares of Privia Health Group in a research note on Thursday, January 2nd. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Buy” and an average price target of $25.18.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.